查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1606318

细胞和基因治疗药物传输设备市场：副产品和非处方药 - 2025-2030 年全球预测

Cell & Gene Therapy Drug Delivery Devices Market by Products (Extension Tube, Infusion Bags, Intravenous Catheter), Commercialized Drugs (Kymriah, Luxturna, Provenge) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年细胞和基因治疗给药设备市场价值为10.8亿美元，预计2024年将达到11.7亿美元，复合年增长率为9.78%，2030年将达到20亿美元，预计将达到80美元百万。

细胞和基因治疗药物传输设备市场涵盖将治疗药物输送到特定细胞和基因以治疗和纠正遗传性疾病和其他重大疾病的创新技术。这些设备对于提高治疗准确性和效率、最大限度地减少脱靶效应并最大限度地发挥治疗潜力至关重要。应用范围涵盖肿瘤学、罕见遗传疾病和免疫性疾病，主要最终用户包括研究机构、医院和生物製药公司。细胞和基因疗法的日益普及、输送系统的技术进步以及基因研究资金和投资的增加推动了成长。将人工智慧整合到个人化治疗方法、开发非病毒传递方法以及与科技和生物技术公司合作建立多功能传递平台方面将会出现机会。策略建议包括技术开发伙伴关係、新兴市场投资以及专注于以患者为中心的交付解决方案。然而，这个市场面临着高成本、严格的监管要求和复杂的製造流程等挑战，这些挑战可能会限制可扩展性和可近性。遗传物料输送固有的复杂性和专门的基础设施需求进一步加剧了这些挑战。创新成熟的领域包括开发新型奈米粒子、脂质载体和旨在提高安全性和有效性的生物分解性聚合物。此外，基于 CRISPR 的递送系统的探索和微流体技术的进步为市场的发展带来了巨大的希望。创新应解决优化交付机制、降低製造成本和提高交付准确性的问题。该市场的特点是技术快速发展和竞争激烈，鼓励不断的研究和合作。相关人员必须仔细掌握监管环境，同时促进满足临床需求和改善治疗结果的创新。

主要市场统计
基准年[2023] 10.8亿美元
预测年份 [2024] 11.7亿美元
预测年份 [2030] 20.8亿美元
复合年增长率（%） 9.78%

市场动态：快速发展的细胞和基因治疗药物输送设备市场的关键市场洞察

细胞和基因治疗药物输送设备市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 慢性病和遗传疾病增加
    • 细胞和遗传疾病药物核准数量增加
    • 需要先进药物传输系统的临床试验和治疗的增加
  • 市场限制因素
    • 药物输送装置高成本
  • 市场机会
    • 奈米技术和生物材料的发展进展
    • 在药物传输中利用人工智慧、机器学习和感测器技术
  • 市场挑战
    • 基因治疗面临复杂的监管挑战以及获得医疗设备核准的困难

波特五力：引领细胞与基因治疗药物传递设备市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对细胞和基因治疗药物输送设备市场的影响

外部宏观环境因素在塑造细胞和基因治疗药物传输设备市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解细胞/基因治疗药物输送设备市场的竞争状况

对细胞和基因治疗药物输送设备市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵细胞和基因治疗药物传输设备市场供应商的绩效评估

FPNV定位矩阵是评估细胞和基因治疗药物传输设备市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，描绘细胞和基因治疗药物传输设备市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对细胞和基因治疗药物输送设备市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病和遗传疾病增加
      • 更多针对细胞和遗传疾病的药物核准
      • 需要先进药物传输系统的临床试验和治疗的增加
    • 抑制因素
      • 药物输送装置高成本
    • 机会
      • 奈米技术的进步和生物材料的开发
      • 在药物传输中利用人工智慧、机器学习和感测器技术
    • 任务
      • 基因治疗复杂的监管挑战和医疗设备核准困难
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章细胞/基因治疗药物传递设备市场：副产品

  • 延长管
  • 点滴袋
  • 静脉导管
  • 预填充式注射器
  • 无菌胰岛素注射器
  • 视网膜下注射插管

第七章按已上市药物分類的细胞/基因治疗药物传输设备市场

  • 基姆里亚
  • 勒克斯图纳
  • Provenge
  • 斯特里姆韦利斯
  • 耶稣宪章
  • 佐尔根斯马

第八章美洲细胞/基因治疗药物传输设备市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太细胞与基因治疗给药设备市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲/中东/非洲细胞/基因治疗药物传输设备市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
  • 战略分析和建议

公司名单

  • Amgen Inc.
  • Bausch & Lomb Incorporated
  • Becton, Dickinson and Company
  • Bluebird bio, Inc.
  • Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC
  • Dendreon Pharmaceuticals LLC.
  • Helixmith Co., Ltd.
  • Kite Pharma, Inc. by Gilead
  • Kolon TissueGene, Inc.
  • Novartis AG
  • Orchard Therapeutics
  • Pfizer, Inc.
  • Renova Therapeutics
  • Spark Therapeutics, Inc.
  • uniQure NV
  • Vericel Corporation
Product Code: MRR-5C6F41F5AF95

The Cell & Gene Therapy Drug Delivery Devices Market was valued at USD 1.08 billion in 2023, expected to reach USD 1.17 billion in 2024, and is projected to grow at a CAGR of 9.78%, to USD 2.08 billion by 2030.

The scope of the market for cell and gene therapy drug delivery devices focuses on innovative technologies that facilitate the targeted delivery of therapeutic agents to specific cells or genes to treat or modify genetic disorders and other major diseases. These devices are essential for improving the precision and efficiency of therapies and minimizing off-target effects, thereby maximizing therapeutic potential. Applications extend across oncology, rare genetic disorders, and immunological conditions, with key end-users including research institutes, hospitals, and biopharmaceutical companies. Growth is driven by the escalating adoption of cell and gene therapies, technological advancements in delivery systems, and increased funding and investments in genetic research. Opportunities emerge in the integration of artificial intelligence for personalization of therapies, development of non-viral delivery methods, and the collaboration between technology firms and biotech companies to create multi-functional delivery platforms. Strategic recommendations include partnerships for technology development, investing in emerging markets, and focus on patient-centric delivery solutions. However, the market faces challenges such as high costs, stringent regulatory requirements, and complex manufacturing processes, which can limit scalability and accessibility. The inherent complexity of genetic material handling and the need for specialized infrastructure further exacerbate these challenges. Areas ripe for innovation include the development of novel nanoparticles, lipid-based carriers, and biodegradable polymers designed to improve safety and efficacy. Additionally, the exploration of CRISPR-based delivery systems and advancements in microfluidic technology offer significant promise for the market's evolution. Innovation should address the optimization of delivery mechanisms, reduction of manufacturing costs, and enhancement of delivery precision. The market is characterized by rapid technological evolution and high competition, encouraging continual research and collaboration. Stakeholders must navigate regulatory landscapes carefully while fostering innovation that aligns with clinical needs and enhances therapeutic outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 1.08 billion
Estimated Year [2024] USD 1.17 billion
Forecast Year [2030] USD 2.08 billion
CAGR (%) 9.78%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Drug Delivery Devices Market

The Cell & Gene Therapy Drug Delivery Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of chronic and genetic disorders
    • Growing number of drug approvals for treatment of cellular and genetic disorders
    • Increasing number of clinical trials and medical treatments requiring advanced drug delivery systems
  • Market Restraints
    • High cost of drug delivery devices
  • Market Opportunities
    • Advancements in nanotechnology and development of biomaterials
    • Utilization of AI, ML, and sensor technologies for drug delivery
  • Market Challenges
    • Complex regulatory challenges of genetic therapies and difficulties with approval of medical devices

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Drug Delivery Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Drug Delivery Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Drug Delivery Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Drug Delivery Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Drug Delivery Devices Market

A detailed market share analysis in the Cell & Gene Therapy Drug Delivery Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Drug Delivery Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Drug Delivery Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell & Gene Therapy Drug Delivery Devices Market

A strategic analysis of the Cell & Gene Therapy Drug Delivery Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Drug Delivery Devices Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Bausch & Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio, Inc., Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC, Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd., Kite Pharma, Inc. by Gilead, Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics, Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Drug Delivery Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Products, market is studied across Extension Tube, Infusion Bags, Intravenous Catheter, Pre-Filled Syringe, Sterile Insulin Syringe, and Subretinal Injection Cannula.
  • Based on Commercialized Drugs, market is studied across Kymriah, Luxturna, Provenge, Strimvelis, Yescarta, and Zolgensma.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of chronic and genetic disorders
      • 5.1.1.2. Growing number of drug approvals for treatment of cellular and genetic disorders
      • 5.1.1.3. Increasing number of clinical trials and medical treatments requiring advanced drug delivery systems
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of drug delivery devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in nanotechnology and development of biomaterials
      • 5.1.3.2. Utilization of AI, ML, and sensor technologies for drug delivery
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory challenges of genetic therapies and difficulties with approval of medical devices
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell & Gene Therapy Drug Delivery Devices Market, by Products

  • 6.1. Introduction
  • 6.2. Extension Tube
  • 6.3. Infusion Bags
  • 6.4. Intravenous Catheter
  • 6.5. Pre-Filled Syringe
  • 6.6. Sterile Insulin Syringe
  • 6.7. Subretinal Injection Cannula

7. Cell & Gene Therapy Drug Delivery Devices Market, by Commercialized Drugs

  • 7.1. Introduction
  • 7.2. Kymriah
  • 7.3. Luxturna
  • 7.4. Provenge
  • 7.5. Strimvelis
  • 7.6. Yescarta
  • 7.7. Zolgensma

8. Americas Cell & Gene Therapy Drug Delivery Devices Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cell & Gene Therapy Drug Delivery Devices Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cell & Gene Therapy Drug Delivery Devices Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Bausch & Lomb Incorporated
  • 3. Becton, Dickinson and Company
  • 4. Bluebird bio, Inc.
  • 5. Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC
  • 6. Dendreon Pharmaceuticals LLC.
  • 7. Helixmith Co., Ltd.
  • 8. Kite Pharma, Inc. by Gilead
  • 9. Kolon TissueGene, Inc.
  • 10. Novartis AG
  • 11. Orchard Therapeutics
  • 12. Pfizer, Inc.
  • 13. Renova Therapeutics
  • 14. Spark Therapeutics, Inc.
  • 15. uniQure N.V.
  • 16. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET RESEARCH PROCESS
  • FIGURE 2. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY EXTENSION TUBE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION BAGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS CATHETER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STERILE INSULIN SYRINGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY SUBRETINAL INJECTION CANNULA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY KYMRIAH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY LUXTURNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PROVENGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STRIMVELIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY YESCARTA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY ZOLGENSMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 41. CHINA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 42. INDIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 43. INDIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. INDONESIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 45. INDONESIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. JAPAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 47. JAPAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 48. MALAYSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 49. MALAYSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. PHILIPPINES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 51. PHILIPPINES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. SINGAPORE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 53. SINGAPORE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. SOUTH KOREA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 55. SOUTH KOREA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. TAIWAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 57. TAIWAN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 58. THAILAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 59. THAILAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. VIETNAM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 61. VIETNAM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 66. DENMARK CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 68. EGYPT CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 70. FINLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 72. FRANCE CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 74. GERMANY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 76. ISRAEL CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 78. ITALY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 80. NETHERLANDS CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 82. NIGERIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 84. NORWAY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. POLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 86. POLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 88. QATAR CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 89. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 90. RUSSIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 92. SAUDI ARABIA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH AFRICA CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 96. SPAIN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 98. SWEDEN CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. SWITZERLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 100. SWITZERLAND CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 101. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 102. TURKEY CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED ARAB EMIRATES CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED KINGDOM CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SIZE, BY COMMERCIALIZED DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 108. CELL & GENE THERAPY DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023